EGFR and non-small cell lung carcinoma: The current standard of care for patients with advanced or metastatic non–small‐cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐activating mutations is treatment with EGFR‐tyrosine kinase inhibitors (TKIs).